Company Overview: Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's and cognitive impairment from mild traumatic brain injury.
Upcoming Presentations: CEO Michael McFadden will present at two healthcare investor conferences in September, with transcripts available on the company's website afterward.
Product Information: The company has developed ZUNVEYL, a new generation acetylcholinesterase inhibitor for Alzheimer's treatment, which aims to have minimal gastrointestinal side effects and targets specific neuronal receptors to enhance cognition.
Forward-Looking Statements: The release includes forward-looking statements about the company's future plans and risks associated with commercialization, regulatory oversight, and market adoption of their products.
ACOG
$5.38+Infinity%1D
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACOG is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACOG is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.350
Low
18.00
Averages
18.00
High
18.00
Current: 5.350
Low
18.00
Averages
18.00
High
18.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$20 -> $18
2025-10-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20 -> $18
2025-10-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Alpha Cognition to $18 from $20 and keeps a Buy rating on the shares after the sale of roughly 4.6M shares of common stock and approximately 949,000 pre-funded warrants to purchase common stock at a price of $6.25 per share earlier this month. The firm is trimming its 12-month price target to account for the equity dilution from the recent financing as well as revisions to its sales forecasts.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
